Blood sampling
BiologicalVenous blood will be sampled for laboratory analyses (see outcomes).
NCT Number: NCT02713581
The primary objective of this study is to search for, in vitro, elements associated with IgG-dependent monocyte activation (signaling pathway activation, expression of pro-coagulant and pro-inflammatory factors) and to describe their prevalence in female patients with a history of proximal venous thromboembolism (proximal deep vein thrombosis or pulmonary embolism) compared to control women.
Looking for future studies?
Notify Me18 year–50 year
Female
Observational
CHRU de Montpellier - Hôpital Saint-Eloi, Montpellier, France
The secondary objectives of this study include to compare the IgG-dependent monocyte activation profiles as a function of laboratory thrombophilia parameters. Essentially: Is IgG-dependent cell activation associated with the presence of anti-phospholipid antibodies (or their subtypes?), or do these profiles indicate something beyond the nosology of anti-phospholipid syndrome?
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for patients:
Exclusion criteria
for patients:
Inclusion criteria
for healthy volunteers:
Exclusion criteria
for healthy volunteers:
Venous blood will be sampled for laboratory analyses (see outcomes).
Time frame: Day (0)
The following will be taken into account: Six signaling pathways (Protein kinase B, extracellular-signal-regulated kinases, Signal transducer and activator of transcription 5, P38 mitogen-activated protein kinases, Mechanistic Target Of Rapamycin, nuclear factor kappa-light-chain-enhancer of activated B cells), increases in the expression of tissue factor, and 5 pro-inflammatory factors (Intercellular Adhesion Molecule, tumor necrosis factor alpha, interferon gamma, Interleukin-1 beta, Interleukin 8). A pathway will be considered as "activated" or an expression profile as "increased" when the observed value is superior to the 95% confidence interval determined using healthy volunteer values. A patient is considered as having an activation profile if at least one of the above pathways or expressions is considered as activated / increased.
Time frame: Day (0)
Time frame: Day (0)
Time frame: Day (0)
Time frame: Day (0)
Time frame: Day (0)
Time frame: Day (0)
Time frame: Day (0)
The presence / absence of a constitutional biological thrombophilia (mutation of the Leiden V factor and the prothrombin gene, deficiency in physiological coagulation inhibitors)
Time frame: Day (0)
Time frame: Day (0)
Centre Hospitalier Universitaire de Nīmes
Other
Acronym: ActiMon
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07689136
Cardiovascular Diseases, Deep Vein Thrombosis
Tunis, Tunisia
View Trial DetailsNCT04737954
Cardiovascular Diseases, Deep Vein Thrombosis
Hamburg, Germany
View Trial DetailsNCT05351749
Arrhythmias, Cardiac, Atrial Fibrillation
Ann Arbor, Michigan, United States
View Trial DetailsNCT04168203
Cardiovascular Diseases, Deep Vein Thrombosis
Boston, Massachusetts, United States
View Trial Details